Brief: Adocia: First Cell Therapy Preclinical Proof of Concept of AdoShell Islets

Adocia SA

07/09/2022 06:39

Sept 7 (Reuters) - Adocia SA  ADOC.PA :
    * ADOCIA ANNOUNCES FIRST CELL THERAPY PRECLINICAL PROOF OF
CONCEPT
OF ADOSHELL® ISLETS FOR THE TREATMENT OF TYPE 1 DIABETES
    * ADOSHELL ISLETS WILL BE EVALUATED IN DIABETIC PIGS IN 4TH
QUARTER OF 2022
    * A NEW SERIES OF DIABETIC RATS, BEING TREATED WITH ADOSHELL
ISLETS, CONFIRM THESE PROMISING RESULTS WITH 80 DAYS
NORMOGLYCEMIA
    * ADOSHELL ISLETS REGULATED GLYCEMIC CONTROL IN
IMMUNOCOMPETENT
DIABETIC ANIMALS IN A 132-DAY TRIAL WITHOUT USE OF INSULIN OR
IMMUNOSUPPRESSION
    * THESE RESULTS WILL BE PRESENTED AT UPCOMING CELL THERAPY
SESSION
OF PODD 2022 CONFERENCE HELD IN BOSTON IN OCTOBER
    * ADDITIONAL ONGOING STUDIES IN DIABETIC RATS, WITH AIM TO
OPTIMIZE ADOSHELL TECHNOLOGY, CONFIRM THESE INITIAL RESULTS,
PRODUCING INSULIN AND NORMALIZING GLYCEMIA IN 4 DIABETIC RATS
FOR 80 DAYS (STUDY STILL ON-GOING)
    * THIS FIRST PROOF OF CONCEPT IN DIABETIC RATS VALIDATES OUR
ADOSHELL TECHNOLOGY - DEPUTY-CEO AND DIRECTOR OF RESEARCH AND
DEVELOPMENT AT ADOCIA

Source text for Eikon:  ID:nBw4TQJTXa 
Further company coverage:  ADOC.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))